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Synapse formation is considered to be crucial for learning and memory. Understanding the underlying molecular mechanisms of
synapse formation is a key to understanding learning andmemory. Kalirin-7, a major isoform of Kalirin in adult rodent brain, is an
essential component of mature excitatory synapses. Kalirin-7 interacts with multiple PDZ-domain-containing proteins including
PSD95, spinophilin, and GluR1 through its PDZ-binding motif. In cultured hippocampal/cortical neurons, overexpression of
Kalirin-7 increases spine density and spine size whereas reduction of endogenous Kalirin-7 expression decreases synapse number,
and spine density. In Kalirin-7 knockout mice, spine length, synapse number, and postsynaptic density (PSD) size are decreased in
hippocampal CA1 pyramidal neurons; these morphological alterations are accompanied by a deficiency in long-term potentiation
(LTP) and a decreased spontaneous excitatory postsynaptic current (sEPSC) frequency. Human Kalirin-7, also known as Duo
or Huntingtin-associated protein-interacting protein (HAPIP), is equivalent to rat Kalirin-7. Recent studies show that Kalirin is
relevant to many human diseases such as Huntington’s Disease, Alzheimer’s Disease, ischemic stroke, schizophrenia, depression,
and cocaine addiction. This paper summarizes our recent understanding of Kalirin function.
1. Kalirin Is a Rho Guanine Nucleotide
Exchange Factor (GEF)
Kalirin was discovered 15 years ago as a novel protein
that interacts with the cytosolic carboxyl-terminal of pep-
tidylglycine α-amidating monooxygenase (PAM), an inte-
gral membrane peptide processing enzyme [1]. We have
made significant progress in understanding the functions of
Kalirin; like the many other Rho-GEFs encoded in mam-
malian genomes, Kalirin promotes the exchange of GDP for
GTP and thus stimulates the activity of specific Rho GTPases
[2, 3]. Rho GTPases that regulate multiple cellular processes
play a key role in transducing signals from extracellular
stimuli to the intracellular pathways that play a pivotal role in
the formation of dendritic spines and synaptic development
[4–6].
2. Multiple Kalirin Isoforms
The mouse Kalirin gene (Kalrn) consists of 65 exons
spanning >650 kb of the genome; the presence of multiple
promoters and transcriptional start sites enables the pro-
duction of multiple functional isoforms of Kalirin [7–9].
Each Kalirin isoform is composed of a unique collection
of domains (Figure 1). Major Kalirin isoforms including
Kalirin-7, -9, and -12 are generated through the use of
alternative 3′ exons [8]. The major isoforms share some
common features including nine spectrin-like repeats, the
GEF1 domain and the Sec14p domain. Sec14p domains
facilitate lipid interactions and cellular localization. The nine
spectrin-like repeat regions that follow the Sec14p domain
have been shown to interact with many proteins including
disrupted in schizophrenia 1 (DISC1) [10], peptidylglycine
α-amidating monooxygenase (PAM) [1], inducible nitric
oxide synthase (iNOS) [11], Huntingtin-associated pro-
tein 1 (HAP1) [12], and Arf6 (ADP-ribosylation factor
6) [13]. Kalirin-12 is the longest isoform and contains
additional domains that include GEF2, an immunoglobulin-
like (Ig) domain, a fibronectin III (FnIII) domain, and a
serine/threonine protein kinase domain that is followed by a
short, unique carboxyl-terminus [7, 14]. Kalirin-12 is found
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Figure 1: Major Kalirin isoforms. Alternative splicing generates different isoforms of Kalirin. DH: Dbl homology; PH: pleckstrin homology;
GEF1: guanine nucleotide exchange factor 1; SH3: Src homology domain; GEF2: guanine nucleotide exchange factor 2; I: immunoglobulin-
like; F: fibronectin III-like; Kin: kinase domain; red lines, unique 5′- and 3′-untranslated regions.
in the growth cones of immature neurons (Figure 2) and
dendritic spines of mature cultured hippocampal neurons,
suggesting a role for Kalirin-12 in axon outgrowth and
synaptic plasticity. Interaction of the Ig-FnIII region unique
to Kalirin-12 with the GTPase domain of dynamin may
facilitate the coordination of endocytic trafficking and
changes in the actin cytoskeleton [15]. Endogenous Kalirin-
9 is localized to neurites and growth cones, and expression
of exogenous Kalirin-9 induces longer neurites and altered
neuronal morphology in cultured cortical neurons [16]. The
functions of Kalirin-9 and Kalirin-12 in neurons remain
to be elucidated. The ΔKalirin-7 (also referred as Kalirin-
5) isoform is generated using a different promoter, and
translation initiation begins at the start of spectrin-like
repeat 5, producing an isoform with only 5 spectrin-like
repeats. Overexpression of ΔKalirin-7 results in an increase
in spine size, but not spine density, in cultured cortical
neurons [17]. Duet, an isoform of Kalirin that begins just
before the second GEF domain and continues through the
unique C-terminal of Kalirin-12, uses a third promoter [7].
Duet was discovered as a protein homologous to the catalytic
domain of death associated protein kinase and is localized
to actin-associated cytoskeletal elements, suggesting the
involvement of Duet in cytoskeleton-dependent functions
[18].
3. Tissue Expression
Kalirin expression is detectable in a wide array of adult
tissues including neurons, endocrine cells, liver, muscle, and
heart [2, 20, 21]. In addition, developmentally regulated,
tissue specific-Kalirin isoform expression is evident. Kalirin-
9 and -12 are highly expressed in neuronal tissue during
embryonic development, while in the adult brain expression
of each is drastically decreased; a concomitant increase in
Kalirin-7 expression occurs [8, 20, 22]. Kalirin-7 expression
is largely limited to neurons of the central nervous system;
its levels are extremely low at birth (postnatal days 1–
7) and begin to increase markedly at postnatal day 14,
which coincides with the onset of maximum synaptogenesis
[22, 23].
4. Kalirin-7 Is the Major Kalirin
Isoform in Adult Brain
Kalirin-7 is the most abundant Kalirin isoform in the
adult rodent brain and is exclusively localized to the
postsynaptic side of excitatory synapses [19, 22, 39, 40].
Kalirin-7 is a multifaceted molecule containing domains that
interact with a wide array of molecular machinery. The
Sec14p domain located at the N-terminus interacts with
phosphatidylinositol-3-phosphate and plays a key role in
Kalirin-7-mediated spine morphogenesis (Ma et al., unpub-
lished). The C-terminus of Kalirin-7 contains a unique PDZ-
binding motif through which Kalirin-7 interacts with PDZ-
domain-containing proteins including PSD-95, AF-6, and
spinophilin [39]. Binding of the NMDA receptor subunit
NR2B to the PH domain of Kalirin-7 is important for
normal synaptic plasticity [41]. The spectrin-like domains
of Kalirin-7 through which it interacts with DISC1, iNOS,
PAM, HAP1, and Arf6 play a key role in Kalirin-7-induced
synapse formation (Ma et al., unpublished). The nucleotide
sequences of human Kalirin-7 (Duo) and rat Kalirin-7 are
91% identical, and their amino acid sequences are 98%
identical; human Kalirin-7 contains a 27-nucleotide insert
not found in rat Kalirin-7, located at the end of the region
encoding the seventh spectrin repeat [8, 12].
5. Kalirin-7 Contains Multiple
Phosphorylation Sites
Phosphorylation of Kalirin-7 has recently been shown to
be a pivotal mechanism mediating Kalirin-7-induced spine
formation and synaptic plasticity [42–44]. Purified PKA,
PKC, CaMKII, Cdk5, and Fyn each phosphorylate purified
Kalirin-7 [45]. Kalirin-7 is extensively phosphorylated in
vivo. The phosphorylation sites identified in vitro using
purified CaMKII, PKA, PKC, or CKII, identified only 5
of the 22 sites that undergo phosphorylation in cells or
tissue. These findings emphasize a critical role for additional
protein kinases and the importance of cellular localization
in the phosphorylation of Kalirin-7 [45]. Densely distributed
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Figure 2: Kalirin-12, not Kalirin-7, is localized to the growth cone of hippocampal neurons. Primary cultures of hippocampal neurons
prepared at embryonic day 20 (E20) were transfected with a vector encoding GFP on the day of culture preparation as described [19].
On day 3 after transfection, cultures were fixed for staining of filamentous actin with Alexa Fluor 633 Phalloidin (Life Technologies) and
endogenous Kalirin-7 or Kalirin-12 with isoform-specific rabbit antibodies. Rabbit antibodies were visualized using Cy3 donkey anti-rabbit
IgG (The Jackson Laboratory). Images were collected with a Zeiss confocal microscope LSM510.
phosphorylation sites have been identified in the spectrin-
like repeat region, many lying on the fourth and fifth
repeats. Their phosphorylation state could influence on a
wide array of protein-protein interactions that involve this
region. Since the first four spectrin-like repeats are absent
in ΔKalirin-7 (Figure 1), the phosphorylation sites in the
missing region could play a key role in the differences in spine
size and density associated with expression of full length
Kalirin-7 versus ΔKalirin-7. Overexpression of exogenous
Kalirin-7 results in an increase in both spine density and
spine size while overexpression of ΔKalirin-7 only increases
spine size without altering spine density [17]. Although
phosphorylation sites that regulate GEF activity as assessed
in intact cells have been identified, a relationship between
phosphorylation state and GEF activity has not yet been
demonstrated using purified proteins.
6. Kalirin-7 Plays a Key Role in
Spine/Synapse Formation In Vitro
Kalirin-7 expression is limited to neurons in the CNS [22, 30,
46]. Immunostaining in cultured hippocampal and cortical
neurons demonstrates that Kalirin-7 clusters are apposed
to glutamate-transporter-1-(Vglut1-) positive clusters, a
marker for excitatory presynaptic terminals [19, 47, 48].
When cultured neurons are fixed with cold methanol, it
can be seen that the Kalirin-7 positive clusters consistently
overlap clusters positive for PSD95, NMDA receptor subunits
NR1 and NR2B, or AMPA receptor subunits GluR1 and
GluR2; overlap is apparent in both dendritic spines and in the
dendritic shaft [19, 40]. In contrast, Kalirin-7 clusters neither
align with GAD65-positive clusters, a marker for inhibitory
presynaptic terminals, nor with GABAA receptor positive
clusters, a marker for inhibitory postsynaptic endings [19].
These findings lead to the conclusion that Kalirin-7 is
localized almost entirely to postsynaptic excitatory terminals.
Regulation of Kalirin-7 expression by synaptic activity in
hippocampal neurons suggests that Kalirin-7 plays a pivotal
role in the regulation of excitatory synapse formation and
signaling [40, 42]. Overexpression of Kalirin-7 causes an
increase in dendritic spine density, spine size, and synapse
number, while reduction of endogenous Kalirin-7 levels leads
to a reduction in spine density, spine size, and synapse
number in cultured hippocampal and cortical neurons
[19, 22, 39] (Figure 3). Interestingly, overexpression of
Kalirin-7 induces spine formation in spine-free hippocampal
interneurons [19] and a recent study reports an important
role of Kalirin-7 in regulating dendrite growth in cortical
interneurons [44]. A delicate balance between synaptic
excitation and inhibition is critical for maintaining normal
circuits in the CNS, and interneurons play an essential role
in regulating local circuit excitability [49]. Understanding
Kalirin-7 function in interneurons may increase our under-
standing of neurological diseases such as epilepsy, bipolar
disorder, schizophrenia, autism, and Alzheimer’s Disease,
which are related to disruption of GABAergic interneuron
development [50–53].
7. Kalirin-7 Plays a Key Role in
Spine/Synapse Formation In Vivo
Two Kalrn knockout mouse models have been developed: the
Kalirin-7 knockout mouse (Kalirin-7KO) [54] and the GEF1
Kalirin knockout mouse (KalirinGEF1−KO) [55]. Kalirin-7KO
mice, in which the terminal exon unique to Kalirin-7 was
deleted, grow and reproduce normally. Hippocampal CA1
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Figure 3: Expression of Kalirin-7 shRNA causes a reduction in spine density and spine size in cultured hippocampal neurons. Cultured
hippocampal neurons prepared at E20 were transfected with vector encoding a membrane-tethered version of GFP (pmGFP) alone [(a),
spine density 8.9 ± 0.8/10 μm], pmGFP plus a scrambled shRNA [(b), spine density 9.2 ± 0.9/10 μm], or pmGFP plus pSIREN-Kalirin-7
shRNA [(c), spine density 5.2 ± 0.6/10 μm] on the day of culture preparation. The specificity of pSIREN-Kalirin-7 shRNA was determined
previously [19]. DsRed marks transfected neurons expressing the shRNA. Images were collected on day 20 with an LSM510 confocal
microscope. Expression of Kalirin-7 shRNA, not scrambled shRNA, caused a 80% decrease in Kalirin-7 staining (not shown). Spine density
was determined using Metamorph (Molecular Devices, Downington, PA) as described [54]. Scale bar = 5 μm.
pyramidal neurons of Kalirin-7KO mice show a 15% decrease
in spine density and deficits in long-term potentiation
(LTP). Morphological alterations in Kalirin-7KO mice are
accompanied by behavioral alterations including decreased
anxiety-like behavior in the elevated zero maze and impaired
acquisition of a passive avoidance task. Kalirin-7KO mice
exhibit normal behavior in the open field, object recognition,
and radial arm maze tasks [54]. PSDs purified from the
cortices of Kalirin-7KO mice show a deficit in Cdk5, a kinase
known to phosphorylate Kalirin-7 and play an essential
role in Kalirin-7-mediated spine formation and synaptic
function [43, 54, 56]. Furthermore, NR2B levels are modestly
decreased in PSD preparations from the cortices of Kalirin-
7KO animals [54]. This decrease is accompanied by decreased
levels of NR2B-dependent NMDA receptor currents in
cortical pyramidal neurons [41]. NR2B plays a critical role in
LTP induction, dendritic spine formation, different forms of
synaptic plasticity, learning, andmemory [57–60]. Decreased
NR2B levels may partially contribute to decreased spine
density and the deficit in LTP induction observed in Kalirin-
7KO mice. Importantly, expression of exogenous Kalirin-
7 in cultured Kalirin-7KO neurons rescues decreased spine
density. These findings show that Kalirin-7 plays an essential
role in synaptic structure and function.
The KalirinGEF1−KO mice were generated by replacing
exons 27-28 in the first GEF domain by a neomycin resistance
cassette, thus eliminating production of the major Kalirin
isoforms; in addition to Kalirin-7, these mice are unable
to produce Kalirin-9 and Kalirin-12 [55]. KalirinGEF1−KO
mice show significant morphological deficits including
reduced size of both cortex and decreased spine density
in pyramidal neurons of the cortex [55]. Interestingly, in
KalirinGEF1−KO mice the hippocampus is reduced in size
but spine density in hippocampal neurons is normal. This
reduction in hippocampal size in KalirinGEF1−KO mice results
from neuronal loss since Kalirin is exclusively expressed in
pyramidal neurons, granule cells of the dentate gyrus, and
interneurons scattered throughout the hippocampus [19, 22,
46, 54]. Both Kalirin-7KO and KalirinGEF1−KO mice show
impaired hippocampal LTP induction, impaired contextual
fear conditioning, and reduced spine density in cultured
cortical neurons and normal long-term memory [54, 61].
KalirinGEF1−KO mice show deficits in working memory and
an intact reference memory. However, Kalirin-7KO and
KalirinGEF1−KO mice exhibit distinct differences in their
behavioral phenotype. KalirinGEF1−KO mice show very high
locomotor activity in the open field and a deficit in spatial
memory, which are not affected in Kalirin-7KO mice [54, 55].
Further comparisons of the phenotypes of the KalirinGEF1−KO
and Kalirin-7KO mice are needed, along with the generation
of additional Kalrn knockout mouse models generated using
different knockout strategies.
8. Kalirin-7 Is Implicated in Cocaine Addiction
Cocaine addiction is a chronic relapsing neurological dis-
order associated with severe medical and psychosocial
complications [62–66]. The long-lasting nature of cocaine
addiction leads to relapse and makes it especially difficult
to treat [21]. Repeated cocaine treatments increase dendritic
spine density/spine head size and neurite complexity in
the brain’s reward circuitry such as the medium spiny
neurons (MSNs) of the nucleus accumbens (NAc). Our study
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Table 1: Kalirin and human diseases.
Kalirin isoform Disease Physiological relevance References
Kalirin-7 (Duo) Schizophrenia
Decreased spine density, decreased Kalirin-7
mRNA levels in the prefrontal cortex
[24]
Kalirin (unknown isoforms) Schizophrenia
Kalirin mRNA increases 2-fold in the
prefrontal cortex
[25]
Kalirin-7 Schizophrenia DISC1 regulates spine formation via Kal7-Rac1 [10]
Kalirin Schizophrenia Kalirin is a risk factor for schizophrenia [26]
Kalirin-7 Alzheimer’s Disease
Decreased levels of Kalirin-7 mRNA and
protein in hippocampus
[27, 28]
Kalirin (unknown isoforms) Animal model of depression
Decreased Kalirin expression in the prefrontal
cortex and hippocampus. ECT increases
Kalirin expression in hippocampus
[29, 30]
Kalirin-7 Animal model of depression
Decreased Kalirin-7 expression in
hippocampus
[31]
Kalirin (unknown isoforms) Animal model of epilepsy Decreased Kalirin expression in hippocampus [32]
Kalirin (unknown isoforms) ADHD Unknown [33]
Kalirin (unknown isoforms) Stroke Unknown [34, 35]
Kalirin (unknown isoforms) Coronary Heart disease Unknown [36]
Kalirin (unknown isoforms) Huntington’s disease
Spectrin-like domains of Kalirin interact with
HAP1
[12]
Kalirin-7
Animal model of cocaine
addiction
An essential determinant of dendritic spine
formation following cocaine treatment
[37, 38]
shows that Kalirin-7 is an essential determinant of dendritic
spine formation following cocaine treatment [38]. Kalirin-
7 is expressed in the MSNs of the NAc, a key area in
the brain involved in drug addiction and reward pathways
[37]. Chronic cocaine treatment of wild-type mice results
in an increase in Kalirin-7 expression in the NAc which is
accompanied by an increase in spine density in the MSNs of
NAc core [37, 67]. This cocaine-induced increase in dendritic
spine density in the NAcMSNs in wild-typemice is abolished
in Kalirin-7KO mice. Both wild-type and Kalirin-7KO mice
have identical spine densities in the MSNs of the NAc
prior to cocaine treatment. These morphological changes
could underlie the behavioral variations seen in these mice
following cocaine treatment. Chronic cocaine treatment
leads to increased locomotor sensitization in Kalirin-7KO
mice compared to wild-type controls [38]. These data
suggest Kalirin-7 plays an important role in the mechanism
of cocaine addiction, which needs to be addressed in the
future.
9. Kalirin Is Implicated in Human Diseases
Altered Kalirin expression has been reported in several
neuropsychiatric, neurological and cardiovascular diseases as
well as animal models of depression, epilepsy and cocaine
addiction (Table 1). Genetic analyses have identified KALRN
as a major risk factor in stroke and early onset of coronary
artery disease [34–36]. Similarly in schizophrenia, decreased
dendritic spine density in the prefrontal cortex is reported
to correlate with decreased Kalirin mRNA levels [24]. A
rare missense mutation in the KALRN gene has been shown
to be a genetic risk factor for schizophrenia [26]. The
spectrin-like repeat region of Kalirin has also been shown to
interact with DISC1, a genetic risk factor for schizophrenia
which plays an important role in activity-dependent spine
elongation by promoting Kalirin-7/Rac-1 interactions [10,
24, 68, 69]. Attention-deficit/hyperactivity disorder (ADHD)
is the most common neurobehavioral disorder and the
underlying molecular mechanisms of ADHD are largely
unknown. Animal models of ADHD are associated with
spine loss in striatal MSNs [70] and functional impairments
in glutamatergic synaptic transmission in the hippocampus
[71]. A genomewide association study of ADHD patients
has also implicated alterations in Kalirin expression in
ADHD [33]. Dendritic pathology and decreased dendritic
spine density are prominent phenomena in early cases of
Alzheimer’s Disease, which correlate significantly with the
progressive decline of mental faculties [72–75]. Alzheimer’s
Disease patients also show a significant decrease in Kalirin
mRNA and protein expression in the hippocampus without
significant changes in other brain regions [28]. This decrease
in Kalirin expression has been associated with increased
iNOS activity both in hippocampus from Alzheimer’s
patients and in cultured neuroblastoma cells [27]. These data
lead to the hypothesis that lack of Kalirin is associated with
the dendritic alterations and substantial decrease in spine
density observed in Alzheimer’s Disease.
The cause underlying major depression and the neurobi-
ological basis of antidepressant therapy are not clear. Altered
synaptic plasticity may play a key role in the pathogenesis
6 Neural Plasticity
and treatment of depression [76]. Major depression is
associated with spine reductions in the hippocampus [77].
Kalirin expression and spine density in the hippocampus are
decreased in the animal models of depression [29, 31, 78].
Kalirin levels and spine density in the hippocampal CA1
pyramidal neurons increase after repeated electroconvulsive
treatment (ECT) [30, 79], one of the most effective therapies
for depression [80, 81]. These observations suggest a role
for Kalirin in the development of depression. In epileptic
patients and in experimental models of epilepsy, there is
a marked spine loss, abnormal spine shape, and alteration
in dendritic morphology in hippocampal CA1 pyramidal
neurons [82, 83]. Animal models of epilepsy show a marked
increase in Kalirin expression in the hippocampus [32],
suggesting a role for Kalirin in the neuropathology of human
epilepsy. Kalirin interacts with Huntingtin-associated pro-
tein 1 (HAP1) [12] and HAP1 dysfunction could contribute
to the selective neuropathology in Huntingtin’s disease [84].
Huntingtin’s disease is characterized by loss of medium-
sized spiny neurons in the striatum [85], alterations in
spine density, and abnormalities in the size and shape of
dendritic spines in striatal MSNs [86–88]. Overexpression of
Kalirin-7 caused an increase in spine density while reduced
expression of Kalirin-7 resulted in loss of dendritic spines
and a decrease in dendritic complexity in the MSNs of
striatal slice cultures which mimic in vivo conditions (Ma
et al., unpublished). These data raise the possibility that
Kalirin-7 may play a role in the neuropathology of Hunt-
ington’s disease [87]. Finally, Kalirn-7 plays an important
role in estrogen-mediated spine/synapse formation in the
hippocampus [31, 40]. Regulation of Kalirin-7 by estrogen
suggests a role for Kalirin in ovarian hormone-associated
cognitive function and menopause-associated disorders [89–
91]. Taken together, altered dendritic spine morphology
and spine density remain the hallmarks of many human
neurological and psychiatric disorders. There is a correlation
between the levels of Kalirin expression and the pathology
of dendritic spines in some psychiatric and neurological
disorders. It is important to understand whether Kalirin is a
trigger or one of many factors mediating the dendritic spine
pathology of these diseases, which may be rescued by altering
Kalirin expression/function or targeting downstream signals
of Kalirin.
10. Conclusion/Future Studies
Kalirin-7, the major isoform of Kalirin in the adult brain,
plays a critical role in spine formation/synaptic plasticity.
Estrogen-mediated spine formation in hippocampal neurons
and cocaine-induced increases in spine density in striatal
MSNs require Kalirin-7. Kalirin has also been implicated
in many neuropsychiatric and neurological diseases. Future
studies will focus on investigating the underlying molecular
mechanisms of Kalirin-7-mediated spine formation/synaptic
plasticity and its role in neuropsychiatric and neurological
diseases.
Acknowledgments
This work was supported by grants DK32948, DA22876,
MH086552, DA032973 from NIH and 11SCA28 from Con-
necticut Innovations. Thanks are due to Drs. DickMains and
Betty Eipper for their comments.
References
[1] M. Rashidul Alam, B. D. Caldwell, R. G. Johnson, D. N.
Darlington, R. E. Mains, and B. A. Eipper, “Novel proteins
that interact with the COOH-terminal cytosolic routing
determinants of an integral membrane peptide-processing
enzyme,” Journal of Biological Chemistry, vol. 271, no. 45, pp.
28636–28640, 1996.
[2] M. R. Alam, R. C. Johnson, D. N. Darlington, T. A. Hand, R.
E. Mains, and B. A. Eipper, “Kalirin, a cytosolic protein with
spectrin-like and GDP/GTP exchange factor-like domains that
interacts with peptidylglycine α-amidating monooxygenase,
an integral membrane peptide-processing enzyme,” Journal of
Biological Chemistry, vol. 272, no. 19, pp. 12667–12675, 1997.
[3] K. L. Rossman, C. J. Der, and J. Sondek, “GEF means go:
turning on Rho GTPases with guanine nucleotide-exchange
factors,” Nature Reviews Molecular Cell Biology, vol. 6, no. 2,
pp. 167–180, 2005.
[4] M. Negishi and H. Katoh, “Rho family GTPases and dendrite
plasticity,” Neuroscientist, vol. 11, no. 3, pp. 187–191, 2005.
[5] K. F. Tolias, J. G. Duman, and K. Um, “Control of synapse
development and plasticity by Rho GTPase regulatory pro-
teins,” Progress in Neurobiology, vol. 94, no. 2, pp. 133–148,
2011.
[6] P. Penzes, K. M. Woolfrey, and D. P. Srivastava, “Epac2-
mediated dendritic spine remodeling: implications for dis-
ease,” Molecular and Cellular Neuroscience, vol. 46, no. 2, pp.
368–380, 2011.
[7] R. C. Johnson, P. Penzes, B. A. Eipper, and R. E. Mains, “Iso-
forms of Kalirin, a neuronal Dbl family member, generated
through use of different 5′- and 3′-ends along with an internal
translational initiation site,” Journal of Biological Chemistry,
vol. 275, no. 25, pp. 19324–19333, 2000.
[8] C. E. McPherson, B. A. Eipper, and R. E. Mains, “Genomic
organization and differential expression of Kalirin isoforms,”
Gene, vol. 284, no. 1-2, pp. 41–51, 2002.
[9] C. E. McPherson, B. A. Eipper, and R. E. Mains, “Kalirin
expression is regulated by multiple promoters,” Journal of
Molecular Neuroscience, vol. 22, no. 1-2, pp. 51–62, 2004.
[10] A. Hayashi-Takagi, M. Takaki, N. Graziane et al., “Disrupted-
in-Schizophrenia 1 (DISC1) regulates spines of the glutamate
synapse via Rac1,”Nature Neuroscience, vol. 13, no. 3, pp. 327–
332, 2010.
[11] E. A. Ratovitski, M. R. Alam, R. A. Quick et al., “Kalirin
inhibition of inducible nitric-oxide synthase,” Journal of
Biological Chemistry, vol. 274, no. 2, pp. 993–999, 1999.
[12] V. Colomer, S. Engelender, A. M. Sharp et al., “Huntingtin-
associated protein 1 (HAP1) binds to a Trio-like polypeptide,
with a rac1 guanine nucleotide exchange factor domain,”
Human Molecular Genetics, vol. 6, no. 9, pp. 1519–1525, 1997.
[13] T. H. Koo, B. A. Eipper, and J. G. Donaldson, “Arf6 recruits
the Rac GEF Kalirin to the plasma membrane facilitating Rac
activation,” BMC Cell Biology, vol. 8, article no. 29, 2007.
[14] C. A. Rabiner, R. E. Mains, and B. A. Eipper, “Kalirin: a dual
Rho guanine nucleotide exchange factor that is so much more
than the sum of its many parts,” Neuroscientist, vol. 11, no. 2,
pp. 148–160, 2005.
Neural Plasticity 7
[15] X. Xin, C. A. Rabiner, R. E. Mains, and B. A. Eipper, “Kalirin12
interacts with dynamin,” BMCNeuroscience, vol. 10, article no.
61, 2009.
[16] P. Penzes, R. C. Johnson, V. Kambampati, R. E. Mains, and B.
A. Eipper, “Distinct roles for the two Rho GDP/GTP exchange
factor domains of Kalirin in regulation of neurite growth and
neuronal morphology,” Journal of Neuroscience, vol. 21, no. 21,
pp. 8426–8434, 2001.
[17] M. R. Schiller, A. Blangy, J. Huang, R. E. Mains, and B. A.
Eipper, “Induction of lamellipodia by Kalirin does not require
its guanine nucleotide exchange factor activity,” Experimental
Cell Research, vol. 307, no. 2, pp. 402–417, 2005.
[18] T. Kawai, H. Sanjo, and S. Akira, “Duet is a novel
serine/threonine kinase with Dbl-Homology (DH) and
Pleckstrin-Homology (PH) domains,” Gene, vol. 227, no. 2,
pp. 249–255, 1999.
[19] X. M. Ma, Y. Wang, F. Ferraro, R. E. Mains, and B. A. Eipper,
“Kalirin-7 is an essential component of both shaft and spine
excitatory synapses in hippocampal interneurons,” Journal of
Neuroscience, vol. 28, no. 3, pp. 711–724, 2008.
[20] D. E. Hansel, M. E. Quin˜ones, G. V. Ronnett, and B. A. Eipper,
“Kalirin, a GDP/GTP exchange factor of the Dbl family,
is localized to nerve, muscle, and endocrine tissue during
embryonic rat development,” Journal of Histochemistry and
Cytochemistry, vol. 49, no. 7, pp. 833–844, 2001.
[21] F. Ferraro, X. M. Ma, J. A. Sobota, B. A. Eipper, and R.
E. Mains, “Kalirin/Trio Rho guanine nucleotide exchange
factors regulate a novel step in secretory granule maturation,”
Molecular Biology of the Cell, vol. 18, no. 12, pp. 4813–4825,
2007.
[22] X. M. Ma, J. Huang, Y. Wang, B. A. Eipper, and R. E.
Mains, “Kalirin, a multifunctional rho guanine nucleotide
exchange factor, is necessary for maintenance of hippocampal
pyramidal neuron dendrites and dendritic spines,” Journal of
Neuroscience, vol. 23, no. 33, pp. 10593–10603, 2003.
[23] D. Muller, P. A. Buchs, and L. Stoppini, “Time course of
synaptic development in hippocampal organotypic cultures,”
Developmental Brain Research, vol. 71, no. 1, pp. 93–100, 1993.
[24] J. J. Hill, T. Hashimoto, and D. A. Lewis, “Molecular
mechanisms contributing to dendritic spine alterations in the
prefrontal cortex of subjects with schizophrenia,” Molecular
Psychiatry, vol. 11, no. 6, pp. 557–566, 2006.
[25] S. Narayan, B. Tang, S. R. Head et al., “Molecular profiles of
schizophrenia in the CNS at different stages of illness,” Brain
Research, vol. 1239, pp. 235–248, 2008.
[26] I. Kushima, Y. Nakamura, B. Aleksic et al., “Resequencing and
association analysis of the KALRN and EPHB1 genes and their
contribution to Schizophrenia susceptibility,” Schizophrenia
Bulletin. In press.
[27] H. Youn, I. Ji, H. P. Ji, W. R. Markesbery, and T. H. Ji, “Under-
expression of Kalirin-7 increases iNOS activity in cultured
cells and correlates to elevated iNOS activity in Alzheimer’s
disease hippocampus,” Journal of Alzheimer’s Disease, vol. 12,
no. 3, pp. 271–281, 2007.
[28] H. Youn, M. Jeoung, Y. Koo et al., “Kalirin is under-expressed
in Alzheimer’s disease hippocampus,” Journal of Alzheimer’s
Disease, vol. 11, no. 3, pp. 385–397, 2007.
[29] A. Alttoa, K. Ko˜iv, T. A. Hinsley, A. Brass, and J. Harro, “Dif-
ferential gene expression in a rat model of depression based
on persistent differences in exploratory activity,” European
Neuropsychopharmacology, vol. 20, no. 5, pp. 288–300, 2010.
[30] X. M. Ma, R. E. Mains, and B. A. Eipper, “Plasticity in
hippocampal peptidergic systems induced by repeated elec-
troconvulsive shock,” Neuropsychopharmacology, vol. 27, no.
1, pp. 55–71, 2002.
[31] W. Li, Q. J. Li, and S. C. An, “Preventive effect of estrogen on
depression-like behavior induced by chronic restraint stress,”
Neuroscience Bulletin, vol. 26, no. 2, pp. 140–146, 2010.
[32] A. K. Sharma, G. H. Searfoss, R. Y. Reams et al., “Kainic acid-
induced f-344 rat model of Mesial temporal lobe epilepsy:
gene expression and canonical Pathways,” Toxicologic Pathol-
ogy, vol. 37, no. 6, pp. 776–789, 2009.
[33] K.-P. Lesch, N. Timmesfeld, T. J. Renner et al., “Molecular
genetics of adult ADHD: converging evidence from genome-
wide association and extended pedigree linkage studies,”
Journal of Neural Transmission, vol. 115, no. 11, pp. 1573–1585,
2008.
[34] M. Bere¸sewicz, J. E. Kowalczyk, and B. Zabłocka, “Kalirin-
7, a protein enriched in postsynaptic density, is involved in
ischemic signal transduction,”Neurochemical Research, vol. 33,
no. 9, pp. 1789–1794, 2008.
[35] T. Krug, H. Manso, L. Gouveia et al., “Kalirin: a novel genetic
risk factor for ischemic stroke,” Human Genetics, vol. 127, no.
5, pp. 513–523, 2010.
[36] L. Wang, E. R. Hauser, S. H. Shah et al., “Peakwide mapping
on chromosome 3q13 identifies the kalirin gene as a novel
candidate gene for coronary artery disease,” American Journal
of Human Genetics, vol. 80, no. 4, pp. 650–663, 2007.
[37] R. E. Mains, D. D. Kiraly, J. E. Eipper-Mains, X. Ma, and
B. A. Eipper, “Kalrn promoter usage and isoform expression
respond to chronic cocaine exposure,” BMC Neuroscience, vol.
12, article 20, 2011.
[38] D. D. Kiraly, X. M. Ma, C. M. Mazzone, X. Xin, R. E. Mains,
and B. A. Eipper, “Behavioral and morphological responses to
cocaine require Kalirin7,” Biological Psychiatry, vol. 68, no. 3,
pp. 249–255, 2010.
[39] P. Penzes, R. C. Johnson, R. Sattler et al., “The neuronal Rho-
GEF Kalirin-7 interacts with PDZ domain-containing proteins
and regulates dendritic morphogenesis,”Neuron, vol. 29, no. 1,
pp. 229–242, 2001.
[40] X.-M. Ma, J.-P. Huang, E.-J. Kim et al., “Kalirin-7, an
important component of excitatory synapses, is regulated by
estradiol in hippocampal neurons,” Hippocampus, vol. 21, no.
6, pp. 661–677, 2011.
[41] D. D. Kiraly, F. Lemtiri-Chlieh, E. S. Levine, R. E. Mains, and
B. A. Eipper, “Kalirin binds the NR2B subunit of the NMDA
receptor, altering its synaptic localization and function,”
Journal of Neuroscience, vol. 31, no. 35, pp. 12554–12565, 2011.
[42] Z. Xie, D. P. Srivastava, H. Photowala et al., “Kalirin-7 controls
activity-dependent structural and functional plasticity of
dendritic spines,” Neuron, vol. 56, no. 4, pp. 640–656, 2007.
[43] X. Xin, Y. Wang, X. M. Ma et al., “Regulation of Kalirin by
Cdk5,” Journal of Cell Science, vol. 121, no. 15, pp. 2601–2611,
2008.
[44] M. E. Cahill, K. A. Jones, I. Rafalovich et al., “Control of
interneuron dendritic growth throughNRG1/erbB4-mediated
kalirin-7 disinhibition,” Molecular Psychiatry, vol. 17, no. 1,
pp. 99–107, 2012.
[45] D. D. Kiraly, K. L. Stone, C. M. Colangelo et al., “Identification
of kalirin-7 as a potential post-synaptic density signaling hub,”
Journal of Proteome Research, vol. 10, no. 6, pp. 2828–2841,
2011.
[46] X. M. Ma, R. C. Johnson, R. E. Mains, and B. A. Eipper,
“Expression of Kalirin, a neuronal GDP/GTP exchange factor
of the trio family, in the central nervous system of the adult
rat,” Journal of Comparative Neurology, vol. 429, no. 3, pp. 388–
402, 2001.
[47] R. T. Fremeau, M. D. Troyer, I. Pahner et al., “The expression
of vesicular glutamate transporters defines two classes of
excitatory synapse,” Neuron, vol. 31, no. 2, pp. 247–260, 2001.
8 Neural Plasticity
[48] R. T. Fremeau, K. Kam, Y. Qureshi et al., “Vesicular glutamate
transporters 1 and 2 target to functionally distinct synaptic
release sites,” Science, vol. 304, no. 5678, pp. 1815–1819, 2004.
[49] G. Maccaferri and J. C. Lacaille, “Interneuron Diversity series:
hippocampal interneuron classifications—making things as
simple as possible, not simpler,” Trends in Neurosciences, vol.
26, no. 10, pp. 564–571, 2003.
[50] F. M. Benes and S. Berretta, “GABAergic interneurons:
implications for understanding schizophrenia and bipolar
disorder,” Neuropsychopharmacology, vol. 25, no. 1, pp. 1–27,
2001.
[51] E. M. Powell, D. B. Campbell, G. D. Stanwood, C. Davis,
J. L. Noebels, and P. Levitt, “Genetic disruption of cortical
interneuron development causes region- and GABA cell type-
specific deficits, epilepsy, and behavioral dysfunction,” Journal
of Neuroscience, vol. 23, no. 2, pp. 622–631, 2003.
[52] D. A. Lewis, T. Hashimoto, and D. W. Volk, “Cortical
inhibitory neurons and schizophrenia,” Nature Reviews Neu-
roscience, vol. 6, no. 4, pp. 312–324, 2005.
[53] B. Ramos, D. Baglietto-Vargas, J. C. D. Rio et al., “Early
neuropathology of somatostatin/NPY GABAergic cells in the
hippocampus of a PS1× APP transgenic model of Alzheimer’s
disease,” Neurobiology of Aging, vol. 27, no. 11, pp. 1658–1672,
2006.
[54] X. M. Ma, D. D. Kiraly, E. D. Gaier et al., “Kalirin-7 is required
for synaptic structure and function,” Journal of Neuroscience,
vol. 28, no. 47, pp. 12368–12382, 2008.
[55] M. E. Cahill, Z. Xie, M. Day et al., “Kalirin regulates
cortical spine morphogenesis and disease-related behavioral
phenotypes,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 106, no. 31, pp. 13058–13063,
2009.
[56] K. O. Lai and N. Y. Ip, “Recent advances in understanding the
roles of Cdk5 in synaptic plasticity,” Biochimica et Biophysica
Acta, vol. 1792, no. 8, pp. 741–745, 2009.
[57] K. Akashi, T. Kakizaki, H. Kamiya et al., “NMDA recep-
tor GluN2B (GluRε2/NR2B) subunit is crucial for channel
function, postsynaptic macromolecular organization, and
actin cytoskeleton at hippocampal CA3 synapses,” Journal of
Neuroscience, vol. 29, no. 35, pp. 10869–10882, 2009.
[58] J. L. Brigman, T. Wright, G. Talani et al., “Loss of GluN2B-
containing NMDA receptors in CA1 hippocampus and cortex
impairs long-term depression, reduces dendritic spine density,
and disrupts learning,” Journal of Neuroscience, vol. 30, no. 13,
pp. 4590–4600, 2010.
[59] T. Ohno, H. Maeda, N. Murabe et al., “Specific involvement
of postsynaptic GluN2B-containing NMDA receptors in the
developmental elimination of corticospinal synapses,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 107, no. 34, pp. 15252–15257, 2010.
[60] A. C. Gambrill and A. Barria, “NMDA receptor subunit com-
position controls synaptogenesis and synapse stabilization,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 108, no. 14, pp. 5855–5860, 2011.
[61] Z. Xie, M. E. Cahill, J. Radulovic et al., “Hippocampal
phenotypes in kalirin-deficient mice,” Molecular and Cellular
Neuroscience, vol. 46, no. 1, pp. 45–54, 2011.
[62] J. Martı´nez-Raga, C. Knecht, and S. Cepeda, “Modafinil: a
useful medication for cocaine addiction? Review of the evi-
dence from neuropharmacological, experimental and clinical
studies,” Current drug abuse reviews, vol. 1, no. 2, pp. 213–221,
2008.
[63] M. J. Smith, J. Thirthalli, A. B. Abdallah, R. M. Murray, and
L. B. Cottler, “Prevalence of psychotic symptoms in substance
users: a comparison across substances,” Comprehensive Psychi-
atry, vol. 50, no. 3, pp. 245–250, 2009.
[64] M. D. Majewska, “Cocaine addiction as a neurological disor-
der: implications for treatment,” NIDA research monograph,
vol. 163, pp. 1–26, 1996.
[65] J. H.Mendelson and N. K.Mello, “Drug therapy: management
of cocaine abuse and dependence,” New England Journal of
Medicine, vol. 334, no. 15, pp. 965–972, 1996.
[66] A. Bu¨ttner, “Review: the neuropathology of drug abuse,”
Neuropathology and Applied Neurobiology, vol. 37, no. 2, pp.
118–134, 2011.
[67] D. D. Kiraly, X. M. Ma, C. M. Mazzone, X. Xin, R. E. Mains,
and B. A. Eipper, “Behavioral and morphological responses to
cocaine require Kalirin7,” Biological Psychiatry, vol. 68, no. 3,
pp. 249–255, 2010.
[68] J. K. Millar, S. Christie, and D. J. Porteous, “Yeast two-hybrid
screens implicate DISC1 in brain development and function,”
Biochemical and Biophysical Research Communications, vol.
311, no. 4, pp. 1019–1025, 2003.
[69] N. J. Bradshaw and D. J. Porteous, “DISC1-binding proteins
in neural development, signalling and schizophrenia,” Neu-
ropharmacology, vol. 62, no. 3, pp. 1230–1241, 2012.
[70] M. L. Berlanga, D. L. Price, B. S. Phung et al., “Multiscale
imaging characterization of dopamine transporter knockout
mice reveals regional alterations in spine density of medium
spiny neurons,” Brain Research, vol. 1390, pp. 41–49, 2011.
[71] V. Jensen, J. E. Rinholm, T. J. Johansen et al., “N-methyl-
d-aspartate receptor subunit dysfunction at hippocampal
glutamatergic synapses in an animal model of attention-
deficit/hyperactivity disorder,” Neuroscience, vol. 158, no. 1,
pp. 353–364, 2009.
[72] C. Tackenberg, A. Ghori, and R. Brandt, “Thin, stubby or
mushroom: spine pathology in alzheimer’s disease,” Current
Alzheimer Research, vol. 6, no. 3, pp. 261–268, 2009.
[73] S. J. Baloyannis, “Dendritic pathology in Alzheimer’s disease,”
Journal of the Neurological Sciences, vol. 283, no. 1-2, pp. 153–
157, 2009.
[74] I. A. Mavroudis, D. F. Fotiou, M. G. Manani et al., “Dendritic
pathology and spinal loss in the visual cortex in Alzheimer’s
disease: a Golgi study in pathology,” International Journal of
Neuroscience, vol. 121, no. 7, pp. 347–354, 2011.
[75] C. Perez-Cruz,M.W. Nolte, M.M. VanGaalen et al., “Reduced
spine density in specific regions of CA1 pyramidal neurons in
two transgenic mouse models of Alzheimer’s disease,” Journal
of Neuroscience, vol. 31, no. 10, pp. 3926–3934, 2011.
[76] O. von Bohlen und Halbach, “Structure and function of
dendritic spines within the hippocampus,” Annals of Anatomy,
vol. 191, no. 6, pp. 518–531, 2009.
[77] A. J. Law, C. S. Weickert, T. M. Hyde, J. E. Kleinman, and
P. J. Harrison, “Reduced spinophilin but not microtubule-
associated protein 2 expression in the hippocampal formation
in schizophrenia and mood disorders: molecular evidence
for a pathology of dendritic spines,” American Journal of
Psychiatry, vol. 161, no. 10, pp. 1848–1855, 2004.
[78] S. D. Norrholm and C. C. Ouimet, “Altered dendritic spine
density in animal models of depression and in response to
antidepressant treatment,” Synapse, vol. 42, no. 3, pp. 151–163,
2001.
[79] F. Chen, T. M. Madsen, G. Wegener, and J. R. Nyengaard,
“Repeated electroconvulsive seizures increase the total number
of synapses in adult male rat hippocampus,” European Neu-
ropsychopharmacology, vol. 19, no. 5, pp. 329–338, 2009.
[80] M. Fink, “Convulsive therapy: a review of the first 55 years,”
Journal of Affective Disorders, vol. 63, no. 1–3, pp. 1–15, 2001.
Neural Plasticity 9
[81] S. M. McClintock, A. R. Brandon, M. M. Husain, and R.
B. Jarrett, “A systematic review of the combined use of
electroconvulsive therapy and psychotherapy for depression,”
The Journal of ECT, vol. 27, pp. 236–243, 2011.
[82] J. C. Fiala, J. Spacek, and K. M. Harris, “Dendritic spine
pathology: cause or consequence of neurological disorders?”
Brain Research Reviews, vol. 39, no. 1, pp. 29–54, 2002.
[83] C. Sgobio, V. Ghiglieri, C. Costa et al., “Hippocampal synaptic
plasticity, memory, and epilepsy: effects of long-term valproic
acid treatment,” Biological Psychiatry, vol. 67, no. 6, pp. 567–
574, 2010.
[84] L. L. Y. Wu and X. F. Zhou, “Huntingtin associated protein 1
and its functions,” Cell Adhesion and Migration, vol. 3, no. 1,
pp. 71–76, 2009.
[85] J.-P. Vonsattel, R. H. Myers, and T. J. Stevens, “Neuropatho-
logical classification of Huntington’s disease,” Journal of
Neuropathology and Experimental Neurology, vol. 44, no. 6, pp.
559–577, 1985.
[86] G. A. Graveland, R. S. Williams, and M. DiFiglia, “Evidence
for degenerative and regenerative changes in neostriatal spiny
neurons in Huntington’s disease,” Science, vol. 227, no. 4688,
pp. 770–773, 1985.
[87] R. J. Ferrante, N. W. Kowall, and E. P. Richardson, “Prolif-
erative and degenerative changes in striatal spiny neurons in
Huntington’s disease: a combined study using the section-
Golgi method and calbindin D28k immunocytochemistry,”
Journal of Neuroscience, vol. 11, no. 12, pp. 3877–3887, 1991.
[88] T. L. Spires, H. E. Grote, S. Garry et al., “Dendritic spine
pathology and deficits in experience-dependent dendritic
plasticity in R6/1 Huntington’s disease transgenic mice,”
European Journal of Neuroscience, vol. 19, no. 10, pp. 2799–
2807, 2004.
[89] M. I. Boulware, B. A. Kent, and K. M. Frick, “The impact
of age-related ovarian hormone loss on cognitive and neural
function,” Current Topics in Behavioral Neurosciences. In press.
[90] E. Scott, Q.-G. Zhang, R. Wang, R. Vadlamudi, and D. Brann,
“Estrogen neuroprotection and the critical period hypothesis,”
Frontiers in Neuroendocrinology, vol. 33, no. 1, pp. 85–104,
2012.
[91] A. Riecher-Ro¨ssler and J. Kulkarni, “Estrogens and gonadal
function in schizophrenia and related psychoses,” Current
topics in behavioral neurosciences, vol. 8, pp. 155–171, 2011.
